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Background: A strong relationship between platelet reactivity and stent thrombosis
(ST) after DES implantation was recently conﬁrmed in the prospective, multicenter
ADAPT-DES study. We herein seek to identify the angiographic predictors of 2-year
ST from this large-scale study.
Methods: Angiographic analyses were performed by an independent angiographic
core laboratory for all ST thromboses. According to a pre-speciﬁed substudy,
propensity-adjusted multivariable analysis was performed to determine angiographic
predictors of 2-year ST.
Results: Among the 8,583 patients included in the ADAPT-DES study, 92 (1.1%) pts
had ST at 2 year of follow-up. Target lesion-related ST were identiﬁed in 77 pts (82
lesions) and clinically matched with 153 pts (196 lesions) without ST. Pts with ST
were more likely to have three vessel disease, longer target lesions, more lesions
containing thrombus, moderate-to-severe calciﬁcation, ACC/AHA type C class, total
occlusions, and in saphenous vein grafts. After propensity-adjusted multivariable
analysis, ACC/AHA type C lesion (HR [95%C] ¼ 1.73 [1.05, 2.86], p¼0.03), the
presence of a total occlusion (HR [95%C] ¼ 1.39 [1.10, 1.76], p¼0.005), and PRU
>208 (HR [95%C] ¼ 1.61 [1.01, 2.57], p¼0.045) were independent predictors of ST
2 years after DES.
Conclusions: From the large-scale ADAPT-DES study, complex lesion (type C) and
total occlusions remain strong angiographic predictors of 2-year ST in the DES era.
Future studies are required to determine methods to reduce ST in the high-risk lesions,
especially in pts with high platelet reactivity on clopidogrel.
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Background: Chronic total coronary occlusion (CTO) is a frequent ﬁnding in patients
with ischemic heart disease. Our aim was to evaluate the prognostic impact of CTO on
long-term survival in patients with different severity of ischemic heart disease at the
level of one whole nation.
Methods: The study population included all consecutive patients registered in the
SCAAR registry (Swedish Coronary Angiography and Angioplasty Registry) from
2005 to 2012 who underwent angiography or PCI in Sweden. Patients with previous
coronary artery bypass graft surgery were excluded. The patients with CTO and
without CTO (no-CTO) were compared using Cox proportional-hazards regression
adjusted for the following covariates: age, indication, extent of coronary artery
disease, smoking, hypertension, hyperlipidemia, diabetes, year of intervention, prior
infarction, prior PCI, hospital and complications. Interaction test was performed
between the presence CTO and the different severity of ischemic heart disease e.g.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrone-vessel disease (1VD), two-vessel disease (2VD), three-vessel disease (3VD) and
left main (LM).
Results: The total of 91,154 patients were included in the study of which 14,609 had
a CTO. Median follow-up was 3 years. The total number of events was 9084. CTO
was an independent predictor of mortality (HR 1.29; 95%CI 1.22-1.37; P<0.001).
There was no interaction between the presence of CTO and severity of ischemic heart
disease (P¼0.32) signifying that CTO is of equal negative prognostic importance in all
subgroups. Compared to 1VD, the mortality risk was higher in 2VD (HR 1.17; 95%CI
1.11-1.24; P<0.001), 3VD (HR 1.47; 95%CI 1.38-1.58; P<0.001) and LM (HR 1.87;
95%CI 1.72-2.02; P<0.001).
Conclusions: Our study is based on the largest CTO cohort so far. The presence of
CTO confers worsening long-term survival in all subsets of coronary artery disease.
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Background: Despite recent high success rates owing to the development of new
strategies such as the retrograde approach, the procedural complications and their
management related percutaneous coronary intervention (PCI) of chronic total
occlusions (CTOs) have not been fully evaluated.
Methods: The aim of this study was to investigate in-hospital outcomes and compare
the frequency of the complications between via the retrograde approach vs. via
antegrade approach. The complications included major adverse cardiac and cerebro-
vascular events (MACCE) (deﬁned as death, myocardial infarction [MI], emergent
coronary bypass surgery, repeat PCI, or stroke), bleeding of clinical signiﬁcance, and
he procedural complications such as acute or sub-acute occlusion, distal embolization,
coronary dissection, and coronary perforation.
Results: Of 1,014 CTOs in 943 patients who underwent PCI between 2005 and 2010,
278 CTOs (27.6%) were attempted using the retrograde approach. The overall
procedural success rate was 92.4% (937/1014). The complication was the second
reason for suspended CTO procedure (7.8%; 6/77). No signiﬁcant difference was
observed in the frequency of the complications between antegrade approach and
retrograde approach except the frequency of coronary perforation that was higher in
the patients treated with retrograde approach. (Table).
Conclusions: Although the higher rate of coronary perforation in the patients treated
with retrograde approach, all cases were solved with optimal treatments in the cath-lab
and in-hospital MACCE was acceptable. Retrograde approach could be the one of the
option for the failed case wi.TCT-53
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Background: Chronic total occlusions (CTO) are complex procedures aiming to
improve the symptoms and outcomes of patients. Although a signiﬁcantly positive
ischemia/viability test is accepted by guidelines as enough to trigger a CTO attempt,
there is still controversy whether silent ischemia patients can beneﬁt as much as
symptomatic patients from this procedure.
Methods: A total of 1343 consecutive patients underwent percutaneous coronary
intervention (PCI) at our center between 2004 and 2013. We compared baseline and
procedural characteristics as well as mid-term outcome in patients with silent or
symptomatic ischemia.acts/ORAL/Miscellaneous Coronary Intervention B17





SResults: Indications for CTO-PCI were mainly: angina in 52.8% of cases, acute coro-
nary syndromes in 13.2%, dyspnea in 3,6%, and silent ischemia in 29.6% (397 cases).
Clinical follow-up was obtained in 92.5% of cases at a mean of 50.228.9 months.
Patients with silent ischemia were older (64.011.8 vs. 62.710.2 years, p¼0.037) and
more frequently diabetics (33.2 vs. 24.9%, p¼0,001). Procedural success rate was
similar (74.6 vs. 74.4%, p¼ns, respectively) as well as all-causes mortality at follow up
(Silent ischemia 10.7 vs. sympt 12.5%, p¼ns) and cardiac death (6.1 vs. 7.4%, p¼ns).
However, patient oriented major adverse cardiovascular and cerebrovascular events
(MACCE) were lower in asymptomatic patients (17.4 vs. 22.7%, p¼0,033), mainly due
to a lower rate of TVR (9.3 vs. 13.3%, p¼0,034) at follow-up.
Conclusions: Our study shows that CTO PCI in patients with silent ischemia is a safe
procedure in experienced hands and that procedural success is a predictor of improved
outcome in this subgroup of patients. Same efforts should be made to offer CTO
recanalization to asymptomatic patients in the presence of ischemia as in symptomatic
patients.
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Background: In this study, we sought to compare the clinical outcomes in patients
undergoing percutaneous coronary interventions (PCI) with transfemoral access using
bivalirudin versus transradial access using heparin or low molecular weight heparin
(LMWH). Recent trend towards transradial PCI is putting pressure on older physicians
to use transradial access. Data suggests that the use of bivalirudin is superior to
heparin when analyzing overall outcomes in coronary PCI via transfemoral approach.
There is a paucity of data when comparing use of bivalirudin in transfemoral coronary
PCI versus transradial coronary PCI with heparin/LMWH.
Methods: 631 patients at a high volume university medical center undergoing coro-
nary PCI were retrospectively divided into two groups (femoral artery access with
bivalirudin and radial artery access with heparin/LMWH). Cardiology fellows ob-
tained access in greater than 90% of all patients.
Results: All-cause mortality, vascular complications, bleeding events within 72 hours,




















MACE 32.0% (33) 22.6% (56) 20.8% (83) 0.059 0.07 0.02 0.55
Death 11.8% (12) 3.7% (9) 4.5% (18) 0.006 0.004 0.007 0.58
Cardiac death 5.9% (6) 2.8% (7) 3.7% (15) 0.39 0.17 0.35 0.52
Non-cardiac death 6.3% (6) 0.8% (2) 0.8% (3) 0.0002 0.003 0.0004 0.95
Death/MI 31.1% (32) 19.7% (49) 16.4% (66) 0.006 0.03 0.001 0.28
Myocardial infarction 22.5% (23) 16.5% (41) 13.8% (55) 0.10 0.22 0.03 0.31
Unplanned
revascularization
1.1% (1) 4.3% (10) 5.8% (22) 0.14 0.16 0.06 0.39
Value are presented as % (n),
MACE¼major adverse cardiac event; MI¼myocardial infarctionConclusions: In this single center study, transradial coronary PCI using heparin or
LMWH has no advantage over transfemoral coronary PCI using bivalirudin in terms
of overall mortality and bleeding outcomes. Further studies to evaluate transradial
coronary PCI using Bivairudin are warranted.
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Background: Treatment of drug-eluting stent in-stent restenosis (DES-ISR) is still
challenging with no established best strategy. The intention of PEPCAD China ISR
was to demonstrate the efﬁcacy of paclitaxel-coated balloon (PCB) angioplasty in
a non-European patient population with DES-ISR.
Methods: PEPCAD China ISR was a 220 patient randomized (1:1), single blind
prospective multicenter trial conducted in China. Patients with DES-ISR receivedB18 JACC Vol 62/18/Suppl B j October 27–Novembeeither PCB (SeQuent Please, B.Braun Melsungen AG, Germany) or paclitaxel-
eluting stent (PES, Taxus Liberté, Boston Scientiﬁc, Natick, MA, USA) treat-
ment. The primary endpoint was in-segment late lumen loss at 9 months.
Secondary endpoints included 9-month % diameter stenosis (DS), binary restenosis
rate, and 12-month target lesion failure (TLF) deﬁned as the composite of cardiac
death, target vessel myocardial infarction or ischemia-driven target lesion revas-
cularization. In addition, deﬁnite/probable stent thrombosis (ST) rates were
documented.
Results: There were no signiﬁcant baseline differences between both treatment groups
in terms of patient, lesion or procedural characteristics. At 9 months, in-segment late
lumen loss in the PCB group was non-inferior to the PES group (0.460.51 mm vs.
0.550.61 mm, difference: -0.06 mm with 95%CI: [-0.23, 0.10], p for non-
inferiority¼0.0005). The 9-month in-segment %DS, binary restenosis, 12-month TLF,
and deﬁnite/probable ST rates were no statistical differences between both treatment
groups (29.0  21.3 vs. 30.8  25.3, p¼0.59; 18.6% vs. 23.8%, p¼0.39; 16.5% vs.
16.0%, p¼0.92; 0.9% vs. 1.0%, p¼1.00, respectively).
Conclusions: In a randomized trial of 220 patients, angioplasty with a PCB was non-
inferior to PES implantation when used to treat DES-ISR. Based upon these as well as
prior randomized trial data, PCB angioplasty offers an effective treatment for DES-
ISR without the necessity of implanting additional metal layers for drug release
(ClinicalTrials.gov identiﬁer: NCT 01622075).
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Background: The treatment of calciﬁed coronary lesions by percutaneous
coronary intervention (PCI) has been shown to be associated with poor
outcomes and an increased rate of complications. However, the impact of
coronary calciﬁcation in patients undergoing coronary artery bypass grafting
(CABG) is unknown.
Methods: Following coronary angiography, CABG was performed in 755 patients
presenting with an acute coronary syndrome (ACS) in the ACUITY trial. Patients
were divided in 3 groups (severe, moderate, none/mild) according to the presence and
extent of calciﬁed coronary lesions as assessed by an independent angiographic core
laboratory. Major ischemic outcomes were assessed at 1 year.
Results: One of more severely calciﬁed lesions was present in 103 (13.6%) patients,
moderate calciﬁcation was present in 249 (33.0%) patients and no/mild calciﬁcation
was present in 403 (53.4%) patients. Patients with severely calciﬁed lesions were more
likely to be older, have lower weight, be smokers, have hypertension and renal
insufﬁciency at baseline. Angiographically, they were more likely to have more
lesions and higher TIMI risk score. There were no differences between groups in the
rates of multivessel disease or number or type (arterial vs. venous) of grafts performed.
The presence of severe calciﬁcation compared to moderate or none/mild was asso-
ciated with a signiﬁcant higher unadjusted rate of death (11.8% vs. 3.7% vs. 4.5%,
p¼0.006), death/MI (31.1% vs. 19.7% vs. 16.4%, p¼0,006) and MACE (32.0% vs.
22.6% vs. 20.8%, p¼0.059) at 1 year. By multivariable analysis, the presence of
severe lesion calciﬁcation was identiﬁed as an independent predictor of 1-year death/
MI (HR 1.77 [95% CI 1.18, 2.66], p¼0.006) and MACE (HR 1.49 [95% CI 1.01,
2.21], p¼0.04).
Conclusions: The presence of severely calciﬁed coronary lesions was associated with
signiﬁcantly worse ischemic outcomes after CABG in patients with ACS.r 1, 2013 j TCT Abstracts/ORAL/Miscellaneous Coronary Intervention
